Micron Technology, Inc. vs 10X Genomics Inc — how do they compare? Micron Technology, Inc. trades at $1,013.88 (market cap $1.16T), while 10X Genomics Inc trades at $67.59 (market cap $8.77B). The key difference: Micron Technology, Inc. is far larger — about 132.3× 10X Genomics Inc's market cap, and Micron Technology, Inc. pays a 0.05% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| MU | TXG | |
|---|---|---|
Market Cap | $1.16T | $8.77B |
Sector | Technology | Health |
52-Week High | $1.21K | $67.29 |
52-Week Low | $140.00 | $11.34 |
Enterprise Value | $1.14T | $8.29B |
Dividend Yield | 0.05% | — |
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,000.26, down 1.61% today but remains in a strong uptrend, supported by bullish technical signals and robust fundamentals. The company reported Q1 2026 EPS of $25.11, beating estimates by 20%, with revenue surging to $37.38 billion in 2025. Operating cash flow hit $17.53 billion, while analyst consensus is strongly bullish with an 82.9% buy rating and a $1,550 price target.
Outlook is positive due to AI-driven memory demand, with 2026 revenue projected at $90.3 billion. Risks include memory market cyclicality and supply constraints, but Micron's margin expansion and institutional support suggest further upside for investors seeking growth in semiconductor equities.
TXG trades at $65.60, up 4.71% today, with a bullish technical signal and recent earnings beats. The stock shows improving fundamentals, with 2025 revenue at $642.82M and net loss narrowing to -$43.54M. Positive sentiment is driven by patent wins, Atera platform demand, and institutional interest, though valuation metrics like P/S of 13.58 and EV/EBITDA of 142.2 remain elevated.
Outlook is cautiously optimistic with upside potential from Atera execution, but risks include high valuation, persistent losses, and competitive pressures. Analyst consensus is mixed with a $50.56 price target below current levels, indicating near-term caution despite long-term growth prospects in genomics.
Trailing returns across standard periods
Latest headlines on both assets
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →